Table. Characteristics of Pediatric Population Receiving Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines From All Data Sourcesa.
| Characteristicb | No. (%) of persons vaccinated | |||
|---|---|---|---|---|
| BNT162b2 (n = 3 920 563) | mRNA-1273 (n = 176 427) | NVX-CoV2373 (n = 53) | Multiple brands (n = 4973) | |
| Age at first dose | ||||
| 6 mo-4 or 5 yc | 256 958 (6.6) | 172 161 (97.6) | 0 | 2299 (46.2) |
| 5 or 6-11 yc | 1 558 895 (39.8) | 1687 (1.0) | 0 | 1471 (29.6) |
| 12-15 y | 1 389 351 (35.4) | 1420 (0.8) | 27 (50.9) | 945 (19.0) |
| 16-17 y | 715 359 (18.2) | 1159 (0.7) | 26 (49.1) | 258 (5.2) |
| Sex | ||||
| Female | 1 954 260 (49.8) | 86 588 (49.1) | 24 (45.3) | 2521 (50.7) |
| Male | 1 965 853 (50.1) | 89 808 (50.9) | 29 (54.7) | 2452 (49.3) |
| Missing or unknown | 450 (0.01) | 31 (0.02) | 0 | 0 |
| Urban vs rural | ||||
| Rural | 191 550 (4.9) | 4465 (2.5) | NR | NR |
| Urban | 3 724 798 (95.0) | 171 771 (97.4) | 50 (94.3) | 4751 (95.5) |
| Missing or unknown | 4215 (0.1) | 191 (0.1) | NR | NR |
| US Department of Health and Human Services region | ||||
| 1 (Connecticut, Maine, New Hamphire, Rhode Island, and Vermont) | 252 282 (6.4) | 15 436 (8.8) | NR | 287 (5.8) |
| 2 (New Jersey, New York, Puerto Rico, and Virgin Islands) | 481 296 (12.3) | 25 927 (14.7) | NR | 1844 (37.1) |
| 3 (Delaware, Washington DC, Maryland, Pennsylvania, Virginia, and West Virginia) | 421 390 (10.8) | 21 765 (12.3) | NR | 455 (9.2) |
| 4 (Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee) | 610 942 (15.6) | 16 869 (9.6) | NR | 523 (10.5) |
| 5 (Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin) | 644 718 (16.4) | 24 061 (13.6) | NR | 465 (9.4) |
| 6 (Arkansas, Louisianna, New Mexico, Oklahoma, and Texas) | 330 374 (8.4) | 11 142 (6.3) | NR | 263 (5.3) |
| 7 (Iowa, Kansas, Missouri, and Nebraska) | 159 328 (4.1) | 6401 (3.6) | NR | NR |
| 8 (Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming) | 168 549 (4.3) | 6998 (4.0) | NR | 203 (4.1) |
| 9 (Arizona, California, Hawaii, Nevada, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands, and Republic of Palau) | 720 576 (18.4) | 37 394 (21.2) | NR | 621 (12.5) |
| 10 (Alaska, Idaho, Oregon, and Washington) | 127 558 (3.2) | 10 260 (5.8) | NR | 203 (4.1) |
| Missing or unknown | 3550 (0.1) | 174 (0.1) | 0 | NR |
| Facility type | ||||
| Hospital | 194 886 (5.0) | 11 492 (6.5) | NR | NR |
| Office | 1 115 926 (28.5) | 125 781 (71.3) | NR | 3559 (71.6) |
| Pharmacy | 1 610 036 (41.1) | 9940 (5.6) | 32 (60.4) | 337 (6.8) |
| Skilled nursing facility | NR | 0 | 0 | 0 |
| Home health agency | NR | 73 (0.04) | 0 | NR |
| Mass immunization center | 110 794 (2.8) | 2448 (1.4) | NR | 121 (2.4) |
| Other | 135 842 (3.5) | 3851 (2.2) | NR | 151 (3.0) |
| Missing or unknown | 751 900 (19.2) | 22 842 (13.0) | NR | 710 (14.3) |
Abbreviation: NR, not reported (data for sample sizes of 1 to 10 and that can be used to back-calculate small cell sizes were masked for confidentiality).
Data are combined from Optum through April 2023, Carelon Research through March 2023, and CVS Health through February 2023. Percentages may not total 100% due to rounding.
Patient characteristics were assessed at the time of first vaccine dose, which was dose 1 or dose 2 depending on the dose that met Emergency Use Authorization–specific dose eligibility criteria; persons who received a different brand of vaccine from their dose 1 are categorized in the multiple brands category.
Children aged 6 months to 4 years who were vaccinated with the BNT162b2 COVID-19 vaccine are included in 6 months to 4 or 5 years age group. Children aged 6 months to 5 years who were vaccinated with the mRNA-1273 COVID-19 vaccine are included in the 6 months to 4 or 5 years age group. Children aged 5 to 11 years who were vaccinated with the BNT162b2 COVID-19 vaccine are included in the 5 or 6 to 11 years age group. Children aged 6 to 11 years who were vaccinated with the mRNA-1273 COVID-19 vaccine are included in the 5 or 6 to 11 years age group.